Editor's note:It is rare that a breakthrough study performed as a graduate student sets the course for the rest of a scientist's distinguished career. But Richard Jude Samulski's study in the early 1980s on an emerging viral vector—adeno-associated virus (AAV)—played a profound role in shaping the evolution of the gene therapy field. Samulski et al. stuck to their beliefs in the clinical potential of AAV, riding out some difficult times for the field to emerge emboldened. Until 2016, Samulski was the head of the Gene Therapy Center at the University of North Carolina School of Medicine. In October 2020, the German big pharma Bayer agreed to acquire Samulski's company AskBio for an impressive $4 billion.

中文翻译：

---

AAV裘德：采访R.裘德萨穆尔斯基

编者注：作为一名研究生完成的突破性研究为科学家的其他杰出职业奠定了基础是很少见的。但是，Richard Jude Samulski 在 1980 年代初对新兴病毒载体——腺相关病毒 (AAV) 的研究在塑造基因治疗领域的发展过程中发挥了深远的作用。萨穆尔斯基等人。坚持他们对 AAV 临床潜力的信念，度过了一些困难时期，使该领域变得更加大胆。直到 2016 年，萨穆尔斯基一直是北卡罗来纳大学医学院基因治疗中心的负责人。2020 年 10 月，德国大型制药公司拜耳同意以惊人的 40 亿美元收购 Samulski 的公司 AskBio。